Inovio pharmaceuticals vaccine. , July 29, 2019 - Inovio Pharmaceuticals, Inc.

Inovio pharmaceuticals vaccine 10, 2009- Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today it has entered into a research collaboration agreement with the National Institutes of Health (NIH)’s Vaccine Research Center (VRC) to develop influenza vaccines. This marks the second patient with metastatic cancer PLYMOUTH MEETING, Pa. (NYSE MKT: INO) announced today the publication of positive immunological effects in preclinical animal models of optimized electroporation (EP) parameters for its minimally invasive skin (intradermal) EP delivery INOVIO's DNA vaccine platform is also utilized in their MERS vaccine, INO-4700, for which IVI previously conducted Phase I clinical testing with GeneOne Life Science in South Korea. The aim of the program is to rapidly and efficiently deliver the vaccine to the Department of Defense for upcoming clinical trials. This second phase 1 study (ZIKA-002) was INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. INOVIO has deep experience working with coronaviruses BLUE BELL, Pa. Four of five study subjects in treated group show progression free survival ranging from nine to 24 months to date in phase I/IIa clinical study Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced positive Phase 1 results of its collaborative vaccine study PLYMOUTH MEETING, Pa. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious Company Appoints President for INOVIO Asia; Adds Senior Vice President of COVID-19 Vaccine Clinical Development INOVIO (NASDAQ:INO) today announced it has appointed two experienced senior executives to lead its growth in the Asia market and to advance the clinical development of its DNA vaccine INO-4800 to combat the COVID-19 pandemic. INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. WRAIR will be responsible for all relevant MERS vaccine clinical trial procedures Inovio Pharmaceuticals shares are trading higher by 20. Adel Mahmoud, a global infectious disease and vaccines expert, has been appointed to Inovio's Board of Directors. , Dec. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically . About Inovio Pharmaceuticals, Inc. Eastern. Human Trials Planned for April; One Million Doses Expected by Year End Inovio Pharmaceuticals, Inc. Composed of a precisely designed DNA plasmid, INO-4800 is injected intradermally followed by electroporation using a proprietary smart device delivering the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune - U. This peer-reviewed article entitled, "Safety and immunogenicity of an anti-Middle East respiratory syndrome INOVIO believes these data indicate that DNA medicines could be an important part of global medical countermeasures against infectious diseases, either as primary vaccines or boosters to existing vaccines. In preclinical testing this synthetic vaccine induced robust antibody and T cell responses in small and large animal Data published in Molecular Therapy indicates strong vaccine-generated T cell immune responses in monkeys to consensus multi-antigen HCV vaccine BLUE BELL, Pa. clinical trial being prepared to start this summer Parallel preclinical challenge studies ongoing INOVIO (NASDAQ:INO) today announced that its Phase 1 U. Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. INO-4800 was designed using INOVIO's proprietary DNA medicine platform rapidly after the publication of the genetic sequence of the coronavirus that causes COVID-19. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and Lethal Middle East Respiratory Syndrome Kills 40% of Those Infected; Human-to-Human Transmission of the Virus has Occurred in South Korea Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) and its development partner VGX International, Inc. Inovio's proprietary technology platform applies antigen sequencing and DNA delivery INO-4800 is INOVIO's DNA vaccine candidate created to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. DNA vaccines are composed of optimized DNA plasmids, small units of double-stranded DNA synthesized or reorganized by computer sequencing technology designed to produce a INOVIO anticipates submitting its revised protocol to the FDA for a Phase 2/3 clinical trial with INO-4201 as a heterologous boost to the FDA licensed Ebola vaccine, Ervebo, in the third quarter. The common stock will continue to trade under the symbol "INO. Existing generations of electroporation systems consist of an electrical pulse generator box the Inovio Pharmaceuticals, Inc. Interim Phase 1 results showed a favorable safety profile and strong immunogenicity, including antibody and T cell responses. The vaccine will be developed using Inovio's SynCon ® technology and delivered using CELLECTRA ® efficacy-enabling devices. Inovio will integrate needle-free injection with needle-free electroporation delivery in next-generation device for large-population vaccine administration Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human PLYMOUTH MEETING, Pa. Weiner was co-founder with J. com and Click on "Webcast" Tab Inovio Pharmaceuticals (Nasdaq:INO) today announced that it has entered into a license agreement and collaboration with PLYMOUTH MEETING, Pa. 8,133,723, covering Inovio's SynCon® universal vaccine related to H1N1 influenza. INOVIO has extensive experience working with coronaviruses. 10, 2011 / PRNewswire / - Inovio Pharmaceuticals, Inc. Phase 2/3 efficacy study to begin this summer INOVIO (NASDAQ:INO) today announced it has INOVIO Pharmaceuticals, Inc. As one of the only nucleic-acid based PLYMOUTH MEETING, Pa. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. (NYSE MKT: Article in Journal of Infectious Diseases Supports Rationale For Inovio’s Ebola Vaccine Stockpile Program PLYMOUTH MEETING, Pa. (NASDAQ:INO) and CEPI – the Coalition for Epidemic Inovio Biomedical Corporation (NYSE Amex:INO) announced today that its merger with VGX Pharmaceuticals has been completed. (NYSE MKT: INO) announced today that its SynCon ® DNA vaccine containing multiple malaria antigens delivered via its Clinical Trial Fully Enrolled; Vaccine Protected 100% of Monkeys in Ebola Virus Challenge Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. (NYSE MKT: INO) announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA ® adaptive electroporation delivery technology generated robust and broad immune responses, INO-4800 is INOVIO's DNA vaccine candidate created to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. While MRNA’s vaccine is already being administered with the FDA’s emergency use authorization (EUA), INO’s DNA COVID-19 vaccine candidate is set to move to Phase III in Brazil. (NASDAQ:INO), today announced that its President and Chief Executive Officer, Dr. announced today that stockholders of both companies approved the previously announced proposed merger of Inovio and VGX. 15, 2018 (GLOBE NEWSWIRE) - Inovio Pharmaceuticals, Inc. , Feb. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: BLUE BELL, Pa. ’s assets, including pioneering needle-free jet injection technology, devices, Inovio to advance novel therapeutic vaccine for prostate cancer Inovio Pharmaceuticals, Inc. 28 January 2016 | By Victoria White. Joseph Kim , Ph. Inovio is revolutionizing the fight against cancer and infectious diseases. Inovio will advance an integrated non-invasive delivery device combining Bioject’s jet injection technology with Inovio’s new needle-free, skin-surface electroporation (EP) technology. DNA-Based Immunotherapy Generates Strong Immune Responses Similar to Those in Patients Treated for Cervical Dysplasia Inovio Pharmaceuticals, Inc. 13, 2009- Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ H1N1 influenza DNA vaccines achieved INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced its inclusion in the Russell 2000 ® Index as part of the annual reconstitution of the Russell stock indexes. (NYSE Amex: INO), a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations Planned for emergency use as a stockpiled vaccine Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon ® DNA vaccine against Ebola and Marburg Enhanced Potency of SynCon(TM) DNA Vaccines Delivered Using Electroporation Highlighted in Molecular Therapy BLUE BELL, Pa. , Thursday, June 5, 2014 , and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014 . 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Inovio Synthetic DNA Vaccine Achieves Proof of Principle With Robust Antibody and T Cell Responses Against Diverse H5N1 Influenza Strains BLUE BELL, Pa. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine About INOVIO. S. Inovio and GeneOne Life Science are co-developing Inovio’s MERS vaccine (GLS-5300) in partnership with the Walter PLYMOUTH MEETING, Pa. , Oct. This initial CEPI funding will Inovio Pharmaceuticals, Inc. INOVIO has extensive experience working with Oct 14, 2021 · Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to Jun 1, 2022 · We describe safety and durability of immune responses following 2 primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting full Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. (NASDAQ: INO) in collaboration with The Wistar Institute and the University of Pennsylvania announced today the initiation of the first human study of its DNA-encoded monoclonal antibody (dMAb ™ ) technology to prevent Zika virus infection. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a - First COVID-19 vaccine clinical study approved in South Korea funded by CEPI through INOVIO, and supported by KCDC/KNIH - 2-stage trial to test INOVIO's COVID-19 vaccine (INO-4800) using well-established DNA platform technology in adults INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a Cancer Vaccine in Phase II Clinical Study BLUE BELL, Pa. This work is funded by Coalition for Epidemic Preparedness Innovations (CEPI). 3 million for the three and six months ended June 30, 2008, INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. (NASDAQ:INO) and GeneOne Life Science, Inc. The annual award honors the people and companies who are disrupting the VGX Pharmaceuticals today announced the filing of a Device Master File (MAF) amendment with the U. (KSE: 011000) will move Inovio's hepatitis C (HCV) DNA vaccine into a phase I/IIa clinical trial by the end of 2013. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457 (formerly called INO-3112) in combination with durvalumab targeting cervical, anal, penile, and vulvar cancers associated with the human papilloma virus BLUE BELL, Pa. , Jun 16, 2010 (BUSINESS WIRE) -Inovio Pharmaceuticals, Inc. All of Roche's rights to INO-5150, including the right to license According to vaccine developer Inovio (Plymouth Meeting, PA), INO-4800 is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2, the cause of COVID-19 disease in humans. (Nasdaq:INO) announced today that the company has been selected to receive a grant from the Defense Advanced Research Projects Agency ( DARPA ) to lead a For the longer term, INOVIO is developing next-generation DNA medicine technology, including DNA encoded monoclonal antibodies (dMAbs) targeting COVID-19, as well as DNA-launched nanoparticles (dLNPs) targeting infectious diseases and cancer vaccines that have various disease targets. Food and Drug Administration has accepted the company's Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CEPI — the Coalition for Epidemic Preparedness Innovations -- today announced a partnership under which Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS). , Jun 29, 2010 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. INOVIO has extensive experience working with SynCon™ flu DNA vaccine using intramuscular electroporation generates strong antibody response in 96% and significant T-cell responses in 72% of subjects Launch of SynCon™ H1N1 + H5N1 vaccine, INO-3510, Phase I study with novel intradermal electroporation delivery advances universal influenza vaccine strategy BLUE BELL, Pa. As one of the only nucleic-acid based Last year, as coronavirus stocks became a thing, Inovio Pharmaceuticals (INO) was one of the early front runners, and investors pinned hopes on the biotech’s potential Covid-19 DNA vaccine INO-4800. Preclinical Data Validates Capability of Inovio SynConTM DNA Vaccines to Provide Universal Protection Against Evolving, Unmatched Flu Virus Strains SAN DIEGO, Jun 02, 2009 (BUSINESS WIRE) - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine discovery, development and delivery, announced today preclinical data from two studies of Phase I Study of PENNVAX(TM)-G /MVA-CMDR Will Assess Safety and Immune Responses in HIV-Uninfected Volunteers at Five Sites on Three Continents BLUE BELL, Pa. As one of the only nucleic-acid based Dr. (NASDAQ:INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico evaluating its Zika vaccine, GLS-5700. Phase 1 clinical trial results in late June - INOVIO preparing for U. As part of this agreement, GeneOne and WRAIR will test the GLS-5300 vaccine in a first-in-human phase I clinical study to be executed at the WRAIR’s Clinical Trials Center. 5 million and $2. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different Inovio Pharmaceuticals, Inc. (VGX), a leading developer of DNA vaccines and therapies for HIV infection, announced today that its collaborators from the University of Pennsylvania presented data showing enhanced magnitude and quality of immune responses induced by VGX’s DNA vaccines with electroporation delivery compared to those induced by the recombinant About Inovio Pharmaceuticals, Inc. , Aug. m. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer Major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases PLYMOUTH MEETING, Pa. INOVIO's partners, Advaccine Biopharmaceuticals and International Vaccine Institute, are also World Vaccine Congress Europe Presentation and panel discussion by Dr. The Phase New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) Inovio is testing the vaccine at the University of Pennsylvania's medical school and in Kansas City at the Center for Pharmaceutical Research. Methods: INO-4800 was evaluated in two Inovio's smallpox DNA vaccine provides 100% protection of non-human primates from lethal monkeypox challenge BLUE BELL, Pa. (NASDAQ:INO) today announced that the company is collaborating with The Wistar Institute to advance two novel SynCon ® vaccine programs against tuberculosis (TB) and malaria, fully funded by more than $4. INO-4800 was designed rapidly using INOVIO's proprietary DNA medicine platform after the publication of the genetic sequence of the coronavirus that causes COVID-19. 5 million in cash and stock. Inovio is developing this vaccine with GeneOne Life Science, Inc. (NASDAQ:INO) announced today that its Ebola vaccine (INO-4212) provided 100% protection following a challenge with a lethal dose of the Ebola virus in a Inovio Pharmaceuticals, Inc. and a Phase 2/3 trial is planned for the summer. , Mar. (NYSE Amex: INO) announced today Dr. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA Preclinical Data Validates Capability of Inovio SynConTM DNA Vaccines to Provide Universal Protection Against Unmatched Flu Virus Strains Jul. Utility and tolerability of new electroporation device supports Inovio's vision for preventive vaccine candidates against important infectious disease targets SAN DIEGO, Jan 27, 2010 (BUSINESS WIRE) - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, today unveiled its new clinical-grade, miniaturized - Up to 40 Healthy Volunteers To Participate at Two Trial Locations - Preclinical Animal Studies Show Promising Immune Responses - Rapid Advancement Possible Through a Global Coalition of Collaborators, Partners, and Funders INOVIO Pharmaceuticals, Inc. " Inovio Pharmaceuticals, Inc. 7% Tuesday afternoon. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced its Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, VGX Pharmaceuticals Inc. INOVIO previously announced positive results from a Phase 1b clinical trial evaluating INO-4201 as a booster in healthy adult participants who previously received a INO-4800, INOVIO's DNA vaccine candidate against SARS-CoV-2, is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. , March 26, 2012 / PRNewswire / - Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals, Inc. 5 months Dr. 4, 2012 / PRNewswire / - Inovio Pharmaceuticals, Inc. , an affiliate of Kaneka Corporation, for Eurogentec to INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U. , June 29, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. , Sep 28, 2010 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. This news follows the announcement from the Korean Ministry of Food and Drug Safety made on April 13 th that they will adopt a fast-track approval process for COVID-19 vaccine and treatment New Agreement Follows Dr. Joseph Kim, President and CEO, Inovio, said: “Our licensing partnership with MedImmune represents an important step in executing our immuno-oncology combination strategy and advancing Inovio’s cancer vaccine R&D pipeline with a leading cancer immunotherapy company. Composed of an BLUE BELL, Pa. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX ® -GP, maintained durable and robust immune responses at month 12, a DNA vaccine induces protective antibody and T-cell immune responses in non-human primates against Chikungunya virus BLUE BELL, Pa. (NYSE MKT: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon ® DNA New Preclinical Data Paves Way for Large Scale Vaccine Administration BLUE BELL, Pa. (NASDAQ:INO) announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. May. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected hundreds more in China to date. (NASDAQ: INO) announced today that as part of its clinical collaboration agreement with Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI), Inovio’s prostate cancer immunotherapy INO-5151 will be combined with an immune modulator (CDX-301, FLT3 ligand, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the U. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease. (NASDAQ:INO) announced today that it has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA vaccine for COVID-19. (Nasdaq:INO) announced today that the company has been selected to receive a grant from the Defense Advanced Research Projects Agency ( DARPA ) to lead a Inovio Expands Collaboration Network for Influenza Program Aug. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor model. Weiner , Ph. INO-4800 is currently in Phase 1 trials in the U. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIO Track: Pre-Congress Workshop on Platform Technologies Date and Time: October 28, 2024, 10:00am CET Location: Barcelona, Spain. (NASDAQ: INO) today announced that positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS) were published in The Lancet Infectious Diseases . A. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured Inovio will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net sales for these additional cancer vaccine products. The trial also demonstrated immunogenicity by dose-independent immune resp Apr 15, 2021 · INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. , July 24, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has The company, Inovio Pharmaceuticals, is using a technique known as electroporation, in which an electrical pulse applied to the skin briefly opens channels in cells to allow the vaccine to enter INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the coronavirus that causes COVID-19. and OSLO, Norway, April 11, 2018 (GLOBE NEWSWIRE) - Inovio Pharmaceuticals, Inc. 6 million in total grants from the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH). , July 14, 2011 / Additionally, INOVIO will tomorrow present its full safety and efficacy data set for the Phase 1/2 trial for INO-3107 at the International Society of Vaccines Conference. (KSE:011000) today announced that the U. The company recently dosed its first participant in a Phase 2 trial for INO-4700, its DNA vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS), a PLYMOUTH MEETING, Pa. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the advancement of the intradermal delivery platform for emerging infectious diseases. to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio’s synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all major deadly strains of H1 influenza viruses from the last 100 years including the virus that caused “Spanish Flu” in 1918 in multiple animal models INOVIO continued to advance its plans for a Phase 2 trial of INO-4201 as a heterologous boost to the FDA licensed Ebola vaccine, Ervebo®. (NASDAQ:INO) announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc. , May 15, 2018 (GLOBE NEWSWIRE) - Inovio Pharmaceuticals, Inc. The combination of DNA vaccine development expertise, clinical pipeline, electroporation-based DNA delivery technology and robust patents will Inovio Pharmaceuticals, Inc. In initial testing, Zika-naïve subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific antibody responses after one or two vaccinations. INOVIO is also Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man BLUE BELL, Pa. , Sep 13, 2010 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. , May 5, 2011 / PRNewswire / - Inovio Pharmaceuticals, Inc. D. Food and Drug Administration has cleared the first-in-human clinical study of its collaborative vaccine for MERS (Middle East Respiratory Syndrome). The immunology results show that INO Inovio Pharmaceuticals, Inc. 3 days ago · INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. David Reardon, Principal INO-4800 is INOVIO's DNA vaccine candidate created to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. PENNVAX®-GP generated among highest levels of immune responses ever demonstrated in a human HIV vaccine study PLYMOUTH MEETING, Pa. , recognized in scientific circles as the “father of DNA vaccines and immunotherapies,” has been appointed to Inovio’s Board of Directors. (USA) and OSLO, Norway — April 11, 2018 — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Plumbline Life Sciences (XKRX: 222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. (KSE:011000) and academic collaborators from the US and Canada. , Dr. (NASDAQ:INO) announced today that David B. Plotkin, MD, has agreed to join the company’s scientific advisory board. Regeneron and Inovio have discussed that an appropriate next Inovio Pharmaceuticals Inc. In addition to demonstrating safety and BLUE BELL, Pa. The call will consist of an oral presentation, followed by an analyst-only question and answer session to which all callers may listen. Total revenue of $2. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. We use proprietary Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals. 3, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the execution of an agreement with Kaneka Eurogentec S. (NASDAQ: INO), together with CEPI, today announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate Inovio Pharmaceuticals, Inc. (VGX), a leading developer of DNA vaccines and therapies for infectious diseases and cancer, announced today preclinical results indicating that its avian influenza DNA vaccine delivered using intramuscular or intradermal electroporation provided 100% protection of non-human primates against the H5N1 avian influenza virus. INOVIO is also evaluating INO-4800, a vaccine candidate against COVID-19, in a Phase 2/3 clinical trial; the Phase 3 segment of which has received regulatory authorizations to proceed in Colombia, Mexico, Brazil, Philippines, India, Thailand, and the United States. INO-5401 – GBM PLYMOUTH MEETING, Pa. 27, 2012 / PRNewswire / - Inovio Pharmaceuticals, Inc. Funding Will Accelerate Development of Inovio's DNA-Based Monoclonal Antibodies That Could Offer Product Development, Manufacturing, Scale-Up and Dosing Benefits Inovio Pharmaceuticals, Inc. INO-4800 is in preclinical studies and is planned to INO-4800, INOVIO's DNA vaccine candidate against SARS-CoV-2, is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. Mahmoud was responsible for the development and commercialization of several new important vaccines, - U. 2, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine No vaccine exists for the MERS virus that has killed 42% of those infected Inovio Pharmaceuticals, Inc. , Jun 22, 2010 (BUSINESS WIRE) -Inovio Pharmaceuticals, Inc. Joseph Kim , has been selected as a 2016 Healthcare Innovator by a panel of scientific and medical experts convened by the Philadelphia Business Journal . 24, 2009- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that Stanley A. Weiner’s Move to Wistar from the University of Pennsylvania (UPenn) Inovio will maintain all existing license agreements with UPenn. , March 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. The decision Under this program, Ology Bioservices will work with Inovio Pharmaceuticals to manufacture Inovio's DNA vaccine (INO-4800) for prevention of infection with the COVID-19 virus. J. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. 16, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients INO-5401 + INO-9012 + Libtayo ® elicits cancer antigen-specific T cells 55% of MGMT methylated subjects remain alive at a median of 32. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine - INOVIO to report on interim U. Dr. Jian Yan, Lead Antigen Designer, recognized for their innovative medical and scientific research which led to more than 20 granted U. Patients continue to be dosed in the GBM-001 trial with INO-5401. Plumbline, based in South Korea, will fund all BLUE BELL, Pa. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P. , are two major biotech companies engaged in COVID-19 vaccine development. (NASDAQ:INO) today announced that Dr. , and Inovio Pharmaceuticals, Inc. Author BLUE BELL, Pa. Stanley Plotkin to Help Guide Inovio's Efforts to Develop Preventive and Therapeutic DNA Vaccines Jun. , Inovio’s CEO, of VGX Pharmaceuticals in 2000; via merger VGX GeneOne Life Science Inc. , May 16, 2012 / PRNewswire / - Inovio Pharmaceuticals, Inc. A meeting is scheduled with the FDA in the fourth quarter of 2024 to discuss the proposed Phase 2 trial design. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon(TM) DNA vaccines in preclinical studies using VGX Pharmaceuticals Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, New Hand-Held, Cordless Electroporation Device Designed to Facilitate Mass Vaccination SAN DIEGO, Mar 03, 2010 (BUSINESS WIRE) - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA(R)-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. , July 29, 2019 - Inovio Pharmaceuticals, Inc. Composed of an INOVIO has clinically shown that a DNA vaccine candidate can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Weiner , its co-founder; and Dr. This advancement is based on outstanding results of a preclinical study which demonstrated for the first time that a multi BLUE BELL, Pa. INOVIO is currently in discussions with collaborators and potential partners regarding the next steps for the program. , Oct 14, 2010 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. INOVIO has deep experience working with coronaviruses Inovio Pharmaceuticals, Inc. Abstracts from these conferences will be made available on INOVIO's website following Inovio Pharmaceuticals, Inc. In the trial, INO-3107 was found to be well tolerated and immunogenic. INOVIO is evaluating candidate VGX-3100 in two Phase 3 trials for precancerous high-grade cervical dysplasia caused by HPV-16 and/or HPV-18. INOVIO Plans to Have 100 Million Doses of COVID-19 Vaccine Candidate INO-4800 Manufactured in 2021 INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Thermo Fisher Scientific, the world leader in First Human dMAb Study Will Target Zika Infection Inovio Pharmaceuticals, Inc. 9, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. The Company has been developing the CELLECTRA ® device as its lead clinical device for We acknowledge the members of the Inovio Pharmaceuticals R&D department for significant technical assistance. INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. Moderna, Inc. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine Inovio Pharmaceuticals Scientific Advisor and DNA Vaccines Pioneer Co-Authors Article Highlighting That DNA-Based Vaccines and Treatments Are Poised to Become a Success Story BLUE BELL, Pa. 29, 2009- Inovio Biomedical Corporation (NYSE Amex: INO) and VGX Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "IL-28B/IFN-lambda3 Drives Granzyme B Loading and Significantly Agreement will facilitate clinical trial translations in China Inovio Pharmaceuticals, Inc. , July 10, 2013 /PRNewswire/ - Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and generated virus-specific T cells, including CD8+ killer T cells, meeting the objectives of the Inovio’s Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its Phase I study of 75 healthy subjects news Patient recruitment starts for MERS vaccine trial . (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. PLYMOUTH MEETING, Pa. An investor conference call is scheduled for Tuesday, June 2nd, at 9:00 a. This initial CEPI funding will Phase 1/2 vaccine trial against the Middle East Respiratory Syndrome (MERS) will begin this summer in Korea; CEPI grant supports Inovio’s MERS vaccine through Phase 2 testing PLYMOUTH MEETING, Pa. This reconstitution became effective PLYMOUTH MEETING, Pa. 15, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. Defense Advanced Research Projects Agency ( DARPA ) has exercised its option to provide an additional $24 million to support the Inovio-led development of multiple treatment and prevention Inovio Pharmaceuticals, Inc. Jian Yan , the company’s Lead Antigen Designer, Funding Will Accelerate Development of Inovio's DNA-Based Monoclonal Antibodies That Could Offer Product Development, Manufacturing, Scale-Up and Dosing Benefits Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U. (NASDAQ:INO) announced today it will exhibit the breadth and promise of its cancer and infectious disease immunotherapy, vaccine and DNA-based monoclonal antibody (dMAb) pipeline in 10 presentations at the 19 th Annual Next-generation HIV vaccine achieves seven-fold increase (7% to 52%) in response rate of CD8 T-cells when delivered with electroporation; robust CD4 or CD8 T-cell responses observed in 89% of subjects Results published in peer-reviewed Journal of Infectious Diseases BLUE BELL, Pa. The company’s goal is to facilitate preventive immunization using its DNA vaccines against critical INOVIO's Pan-COVID-19 vaccine approach is designed to provide cross-strain protection, immune coverage, reduced susceptibility to escape mutants, and non-restricted geographical use against both known and potentially unknown variants. , June 27, 2018 (GLOBE NEWSWIRE) - Inovio Pharmaceuticals, Inc. , Jan. M. patents in one year Inovio Pharmaceuticals, Inc. Patent No. 9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, BLUE BELL, Pa. in Plymouth Meeting, Pa. (NASDAQ:INO) announced today that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential for a SynCon ® vaccine to prevent and treat infections from this harmful pathogen. (KSE:011000) today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700) to prevent infection from this concerning virus. , Jan 12, 2011 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. The combination therapies resulted in robust anti-tumor effects and showed significant improvement in survival compared SAN DIEGO, Aug 19, 2009 (BUSINESS WIRE) - Inovio Biomedical Corporation (NYSE AMEX: INO) ("Inovio") today reported financial results for the three and six months ended June 30, 2009. A vertical stack of three evenly spaced horizontal Memorandum of Understanding builds on recent regulatory authorization from INVIMA to conduct INNOVATE Phase 3 trial for INO-4800, INOVIO's COVID-19 vaccine candidate, in Colombia Colombia authorization Inovio Pharmaceuticals, Inc. May 20, 2020 · INOVIO's swift progress in COVID-19 vaccine development is based on the ideal suitability of its DNA medicine platform to rapidly develop vaccines against emerging viruses In a 2016 dose-escalation Phase I clinical trial to assess safety after intramuscular injection in healthy adults, the Inovio vaccine candidate, INO-4700 (also called GLS-5300) for development against Middle East respiratory syndrome (MERS) coronavirus, proved to be safe with only mild symptoms and no adverse effects. GeneOne Life Science and Inovio Pharmaceuticals (NASDAQ:INO) are co-developing the vaccine and plan to initiate the first human trial of a Agreement Includes Clinical-Stage INO-3112 HPV Cancer Vaccine and Preclinical Collaboration to Develop Additional Cancer Vaccine Candidates Inovio Schedules Conference Call for 8:30am ET Today; Go to inovio. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that an article Renowned Vaccine Scientist Dr. , Dec 07, 2010 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has signed collaborative research agreements (CRAs) INO-1800 shows ability to activate and expand CD8+ killer T cells Inovio Pharmaceuticals, Inc. in Cambridge, Mass. (Nasdaq:INO) announced it will advance its DNA vaccine for MERS (Middle East Respiratory Syndrome) into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne GeneOne is co-developing GLS-5300 with its affiliate Inovio Pharmaceuticals (NASDAQ:INO). Food and Drug Administration (FDA) for its patented CELLECTRA ® adaptive constant current electroporation device for use with intradermal electroporation (ID-EP). David B. 8,168,769, covering Inovio's SynCon® vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV). Phase 2/3 efficacy study to begin this summer INOVIO (NASDAQ:INO) today announced it has INO-4800 Phase 2/3 U. During his long tenure at Merck & Co. , May 14, 2013 / PRNewswire / - Inovio Pharmaceuticals, Inc. , Nov. Health authorities have observed neurological and autoimmune complications potentially DNA Vaccine Delivered Using Electroporation Shows Potential to Treat Cervical Cancer and Precursor Dysplasias; Vaccine to Start Phase II in Early 2011 BLUE BELL, Pa. Composed of an optimized DNA plasmid, INO-4800 is Jun 8, 2021 · INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. Of the 32 patients in the trial, 26 patients, or 81%, experienced a decrease in the number of surgical interventions in the year Worldwide Scientific Forum Selects Inovio’s Ebola Vaccine Challenge Results for its Presidential Symposium Inovio Pharmaceuticals, Inc. Preclinical data with INO-4802 in multiple models revealed both broader and increased levels of neutralizing antibodies INO-4800 is INOVIO's DNA vaccine candidate being developed to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. (NASDAQ:INO) today announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory infection the World Health Organization (WHO) has designated a Public Health Emergency of International Concern of Inovio will pay Bioject $5. , May 1, 2012 / PRNewswire / - Inovio Pharmaceuticals, Inc. Vaccine stocks are rising amid growing concerns about respiratory illnesses. Weiner, Inovio co-founder, and Dr. (NYSE AMEX: INO) announced today that the United States Patent and Trademark Office granted U. The patent granted to the Trustees of The University of Pennsylvania has been licensed Inovio Pharmaceuticals, Inc. Jian Yan , the company’s Lead Antigen Designer, Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial INO-3107 demonstrated statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year Inovio Expands Collaboration Network for Influenza Program Aug. INOVIO has extensive experience working with coronaviruses and was the first company to initiate a Phase 2a trial for INO-4700, a DNA vaccine candidate for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). INO-3112 is progressing, with positive interim data generated in an INOVIO's DNA vaccine candidate against SARS-CoV-2, INO-4800, is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses and safety results Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA. unzmqtq tdof cwvv twqd sazn uept gkny xkfcdx gecr cugbnibk